期刊文献+

Developing new drugs from annals of Chinese medicine 被引量:2

原文传递
导出
摘要 Developing new pharmaceuticals requires massive amounts of time,money and efforts.The key step is how to find a safe and effective entity for a disease condition and how to develop it as new drug effectively.Unfortunately,the FDA’s rate of approving new entities has declined dramatically in the last three decades.There is a strong need to review the current strategy and to optimize process in developing new drugs,both to shorten the process and increase the success rate.Chinese medicine has used natural products to treat patients for thousands of years,and Chinese medicine practitioners have chronicled the patients and treatment methods for thousands of years.There is much information that has not yet been used.The success stories of artimisinin and arsentic trioxide are wonderful examples of how the annals of Chinese medicine can provide leads for discovering new drugs.This paper argues that the annals of Chinese medicine are valuable and describes how they can be used in modern drug discovery.The major topics addressed are:(i)why Chinese medicine is a rich resource for finding new drugs;(ii)how to identify a potential valuable record from Chinese medicine annals;(iii)when a potential valuable record is identified from annals,how to proceed;and(iv)both why and how the approach used for chemical drugs should be revised for drugs based on the historical documents related to herbal medicine.In conclusion,we argue here that the annals of Chinese medicine offer not only a rich resource for new drugs,but also several centuries of patient data with regard to safety and efficacy,that in effect represent pilot studies.Acknowledging and using these data can shorten new drug discovery time and improve efficiency of the drug development process,bringing more effective,safe drugs to market much more quickly and cheaply.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS 2012年第1期1-7,共7页 药学学报(英文版)
  • 相关文献

参考文献1

二级参考文献27

  • 1Moher D,Soeken K,Sampson M,et al.Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine.BMC Pediatr,2002,2(1):3.
  • 2Linde K,ter Riet G,Hondras M,et al.Systematic reviews of complementary therapies-an annotated bibliography.Part 2:Herbal medicine.BMC Complement Altern Med,2001,1:5.
  • 3Liu JP,Kjaergard LL,Gluud C.Misuse of randomization:a review of Chinese randomized trials of herbal medicines for chronic hepatitis B.Am J Chin Med,2002,30(1):173-176.
  • 4Linde K,Jonas WB,Melchart D,et al.The methodological quality of randomized controlled trials of homeopathy,herbal medicines and acupuncture.Int J Epidemiol,2001,30(3):526-531.
  • 5Sackett DL,Straus SE,Richardson WS,et al.Evidence-based medicine:how to practice and teach EBM.2nd ed.London:Churchill Livingstone,1997.
  • 6Schultz KF,Chalmers I,Hayes RJ,et al.Empirical evidence of bias.Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.JAMA,1995,273(5):408-412.
  • 7Moher D,Pham B,Jones A,et al.Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet,1998,352(9128):609-613.
  • 8Moher D.CONSORT:an evolving tool to help improve the quality of reports of randomized controlled trials.Consolidated Standards of Reporting Trials.JAMA,1998,279(18):1489-1491.
  • 9Moher D,Cook DJ,Jadad AR,et al.Assessing the quality of reports of randomized trials:implications for the conductof meta-analyses.Health Technol Assess,1999,3(12):i-iv,1-98.
  • 10Altman DG,Schulz KF,Moher D,et al.The revised CONSORT statement for reporting randomized trials:explanation and elaboration.Ann Intern Med,2001,134(8):663-694.

共引文献36

同被引文献20

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部